Immune response-associated gene expression profiling for biomarker development in hypermutated tumors
Description: Hypermutator tumors from 108 cancer patients with more than 500 SNV (20 TMB) were analyzed in terms of immune response-associated gene expression with aiming at the identification of biomarkers associated prognosis. In hypermutator tumors, specific T-cell activating genes, such as PD-L1, TNFSF9, IL-6, GZMB and CD3G, were upregulated in expression, which may suggest the functional activation of intratumoral T-cells. Hypermutator tumors with immune-inflamed signature (PD-L1+CD8+) showed a better prognosis compared with other immune types. Therefore, not only a hepermutation, but also the initiation of TIL induction against tumor-specific neoantigens in the tumor can be needed to obtaion a better cancer prognosis.
Amount: ¥4,940,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2017-04-01
End date: 2020-03-31
Investigator: Yasuto Akiyama
Institution: Shizuoka Cancer Center Research Institute
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 16
Funder award ID: 17K07209
OpenAlex ID: G1142213800